DELFI Diagnostics Inc, a developer of next-generation, blood-based tests to help detect cancer, announced on Thursday the appointment of Cindy Soriano as chief financial officer, effective immediately.
Soriano brings 20 years of finance leadership to the role. Prior to joining DELFI, she held senior finance leadership roles across the life sciences sector, including leading the finance organisation at Zogenix through its acquisition by UCB and post-transaction integration. Earlier, Soriano held various leadership roles at BioMarin Pharmaceuticals supporting operational and strategic planning across a diverse portfolio of assets spanning pre-clinical, clinical, and commercial stages.
Susan Tousi, DELFI's CEO, said: "Cindy's promotion comes at a pivotal moment for DELFI as we prepare to achieve key clinical and regulatory milestones. Over the past three and a half years as vice president of Finance and Investor Relations, Cindy has been instrumental in building our financial foundation and guiding us through two successful fundraising rounds. Her strategic vision, operational rigour, and collaborative approach will be essential as we work to deliver on our mission and create long-term value."
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
DELFI Diagnostics names new chief financial officer
Organon signs commercialisation agreement for Nilemdo across six European markets